rs63751105
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.2292G>A(p.Trp764*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant changes 1 nucleotide in exon 14 of the MSH2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with Lynch syndrome (PMID: 15945244, 16736289, 16810763). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The p.W764* pathogenic mutation (also known as c.2292G>A), located in coding exon 14 of the MSH2 gene, results from a G to A substitution at nucleotide position 2292. This changes the amino acid from a tryptophan to a stop codon within coding exon 14. This mutation, designated as p.W764X, has been reported in patients from various ethnicities who meet Amsterdam criteria (Czakó L et al. Orv Hetil, 2005 May;146:1009-16; Spaepen M et al. Fam Cancer, 2006;5:179-89; Wang XL et al. World J Gastroenterol, 2006 Jul;12:4074-7). A similar alteration (c.2291G>A) resulting in the same premature stop codon (designated p.Trp764X) as been reported in an individual with the Muir-Torre variant of Lynch syndrome whose colorectal cancer and hepatocellular carcinoma both demonstrated high microsatellite instability and MSH2-/MSH6- by IHC (Casper M et al. Scand J Gastroenterol, 2013 Mar;48:344-51). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Lynch syndrome Pathogenic:1
Coding sequence variation introducing premature termination codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Trp764*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 15945244, 16736289, 16810763). ClinVar contains an entry for this variant (Variation ID: 90949). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at